Glaukos Reports Fourth Quarter and Full Year 2025 Financial Results

Published on February 18, 2026
ALISO VIEJO, Calif.—Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, has announced its fourth quarter and full year 2025 financial results. Net sales in the fourth quarter of 2025 climbed to $143.1 million, a 36 percent increase (34 percent in constant currency) compared with the $105.5 million recorded in the same period of 2024. For the full year, Glaukos achieved net sales of $507.4 million, reflecting a 32 percent growth on both a reported and constant currency basis, compared with the $383.5 million reported in 2024, the announcement said.
Continue reading on website
Other news

EYECON Unveils EYECON[VERSATIONS] Programming, Special Events Lineup for NYC Eyewear Design Week

February 18, 2026
NEW YORK—EYECON, the three-day, design-led luxury eyewear event, has announced the 2026 edition of its EYECON[VERSATIONS] on-site programming and curated special events. EYECON will take place at The Glasshouse during NYC Eyewear Design Week on March 6–8, 2026. This year’s EYECON[VERSATIONS] lineup brings together influential voices from eyewear, retail, design and optometry to explore the ideas s

OSA Linked to Increased Risk of AMD

February 18, 2026
Intermittent hypoxia, a characteristic of obstructive sleep apnea, is known to induce oxidative stress, inflammation and endothelial dysfunction—pathways implicated in the pathogenesis of AMD. Photo: NEI. Click image to enlarge. Obstructive sleep apnea (OSA) shares key pathogenic mechanisms with age-related macular degeneration (AMD) and understanding whether OSA increases A